People develop allergies to various animals, such as cats and dogs, when they are exposed to these animals. Allergies are characterized by a runny nose, itchy eyes, sneezing, nasal congestion, and skin rash. Allergies to cats are allergic reactions in humans to allergens produced by cats. Cat allergens, especially the Fel d1, are available abundantly in the form of dander and are considered key growth driver boosting the demand for allergic asthma worldwide. The first defense mechanism for allergic patients is to avoid being present in and around cats. Certain allergy treatments and autoimmune disease shots, can aid in controlling cat allergy symptoms in humans. Such initiatives may increase the sales growth of cat allergy in humans market in the long run.
As per Pet data, the rate of adoption for dogs in China in 2018 was 11.8 percent, whereas this adoption rate for cats was 19.9 percent. Increased R&D for vaccines and medications for the prevention or treatment of pet allergy is projected to create revenue generation opportunities for the cat allergy in the human market globally. Pet humanization is becoming a widely used trend in the animal feed industry, as most of the pet owners want to offer human-like products or experiences for their pets.
Geographically, North America emerged as the largest revenue generator for the global cat allergy in humans market on account of the high rate of cat adoption as pet. Additionally, the fact that cats are lower maintenance in comparison to other pets that require more attention, pet training, and other perks makes cat adoption rate higher. The high rate of cat adoption and increasing prevalence of cat infection and cat allergy in humans will further help this region continue to dominate the market in the coming years as well.
Get Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84817
The primary factors driving the market are the increasing cases of multiple pet allergy types, growing investments by manufacturers in the creation of revolutionary cat allergy therapeutics, and the growing importance of self-medication. According to Allergy, Asthma & Immunology Research, allergies to both cats and dogs affected 10% to 20% of the world population in the year 2018, thus, resulting in allergic asthma and allergic rhinoconjunctivitis. Such factors are projected to boost the future market demand for cat allergy in humans market in future.
High Allergic Reaction Rate in Children Adds Impetus to Market Growth
According to an article that was published by Allergy U.K., children born into allergic families have a higher risk to develop allergies than other children. Being atopic refers to an increase in the natural inclination of children and their families to develop allergy symptoms as a result of genetic links. As per researchers, the majority of children from atopic families are prone to have allergies themselves. However, in young kids from non-atopic families, 1 in 5 children will become allergic to something. The rising cases of allergy symptoms in young children is projected to serve as another growth driver creating revenue generation opportunities for the cat allergy in humans market in the near future.
Make an Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=84817
Leading players in the global cat allergy in humans market are making efforts to create better medications for treating cat allergy in humans. They are thus, investing heavily on research and development strategies to ensure their brand name in a significant position in the overall market competition. Some of the players are also indulging in merger and acquisition strategies to ensure revenue generation on the one side and maintaining their brand name on the other. Notable players of the global cat allergy in humans market include Merck & Co., Pharmacia Upjohn Co., Aventis Pharmaceuticals, Bristol Meyers Squibb, Glaxo SmithKline, Covis Pharma B.V., Bayer AG, Sanofi, Saiba Animal Health AG, Stallergenes Greer., and others. Major investments in different treatment types such as leukptriene inhibitors, antihistamines, decongestants, and others will help players gain a competitive edge in the market competition, provided they receive FDA approvals at the earliest possible.